The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...